Triple-Drug cocktail targets stomach cancer that has spread to the abdomen

NCT ID NCT07149090

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of three drugs—lenvatinib, nivolumab, and chemotherapy—in people with advanced stomach cancer that has spread to the lining of the abdomen and caused fluid buildup (ascites). The goal is to see if this triple therapy can shrink tumors and help patients live longer without the cancer getting worse. The trial is enrolling 61 participants and includes two phases: first to find the safest dose, then to measure how well it works.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
lenvatinib, nivolumab, and chemotherapy (capecitabine + oxaliplatin)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced gastric cancer and malignant ascites, potentially slowing disease progression and extending life.
What could go wrong
This is an early-phase trial (Phase 1/2) with only 61 participants, so results are preliminary. The drug combination may cause significant side effects, and it is not yet known if it will work better than standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Asan Medical Center

    RECRUITING

    Seoul, 05505, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.